POTS

Baloncibart Phase 2 Signal in POTS

Regeneron disclosed randomized Phase 2 PINNACLE results for NPR1-blocking baloncibart in postural orthostatic tachycardia syndrome. The 450 mg dose lowered the day-eight standing heart-rate increment versus placebo by a least-squares mean 11.4 beats per…